See more : E-L Financial Corporation Limited (ELFIF) Income Statement Analysis – Financial Results
Complete financial analysis of Galectin Therapeutics Inc. (GALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galectin Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Packaging Corporation of America (PKG) Income Statement Analysis – Financial Results
- Oeneo SA (0O33.L) Income Statement Analysis – Financial Results
- Schroders plc (SDRC.L) Income Statement Analysis – Financial Results
- The Shyft Group, Inc. (SHYF) Income Statement Analysis – Financial Results
- AEye, Inc. (LIDRW) Income Statement Analysis – Financial Results
Galectin Therapeutics Inc. (GALT)
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.00K | 32.00K | 41.00K | 36.00K | 35.00K | 0.00 | 1.00K | 7.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 6.46M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -33.00K | -32.00K | -41.00K | -36.00K | -35.00K | 0.00 | -1.00K | -7.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.33M | -6.46M | -7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.13M | 31.74M | 23.82M | 17.98M | 7.47M | 6.47M | 11.72M | 15.33M | 13.11M | 8.43M | 5.69M | 4.53M | 3.55M | 1.07M | 1.11M | 1.77M | 2.05M | 3.02M | 3.04M | 3.04M | 1.95M | 1.48M | 893.46K | 100.00K |
| General & Administrative | 5.90M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Selling & Marketing | 44.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.94M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Cost & Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Interest Income | 0.00 | 52.00K | 3.00K | 66.00K | 231.00K | 38.00K | 24.00K | 45.00K | 52.00K | 42.00K | 16.00K | 24.00K | 18.00K | 6.00K | 3.00K | 30.00K | 102.00K | 281.00K | 111.00K | 124.00K | 68.93K | 24.26K | 24.92K | 0.00 |
| Interest Expense | 2.56M | 1.03M | 489.00K | 87.00K | 87.00K | 336.00K | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 350.00K | 1.85M | 0.00 | 0.00 | 3.88K | 415.42K | 0.00 | 0.00 |
| Depreciation & Amortization | 38.07M | 32.00K | 41.00K | 36.00K | 35.00K | 1.00K | 1.00K | 7.00K | 7.00K | 10.00K | 12.00K | 9.00K | 9.00K | 12.00K | 37.00K | 49.00K | 64.00K | 67.00K | 81.00K | 81.00K | 89.17K | 211.18K | 159.47K | -20.00K |
| EBITDA | -202.00K | -37.71M | -30.00M | -23.34M | -13.17M | -13.56M | -16.23M | -21.47M | -20.07M | -15.78M | -12.08M | -9.67M | -10.91M | -5.62M | -7.43M | -3.10M | -9.02M | -1.28M | -6.77M | -7.10M | -4.85M | -3.08M | -2.02M | -190.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -38.07M | -38.35M | -30.18M | -23.44M | -13.44M | -13.60M | -16.25M | -21.48M | -20.08M | -15.43M | -12.10M | -9.90M | -10.41M | -4.88M | -6.09M | -5.33M | -6.46M | -7.05M | -6.66M | -7.30M | -4.94M | -3.29M | -2.18M | -170.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.99M | -424.00K | -348.00K | -21.00K | 144.00K | -298.00K | 12.00K | 45.00K | 52.00K | -358.00K | 16.00K | 224.00K | -506.00K | -746.00K | -1.37M | 2.18M | -2.98M | 3.86M | 111.00K | 124.00K | 65.05K | -391.16K | 0.00 | -20.00K |
| Income Before Tax | -41.07M | -38.78M | -30.53M | -23.47M | -13.29M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | 0.00 | -190.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 424.00K | 448.00K | 51.00K | 87.00K | -123.14K | 24.00K | 0.00 | 0.00 | -52.00K | 16.00K | 200.00K | 506.00K | 746.00K | 1.37M | -2.18M | 2.98M | -3.86M | 0.00 | 0.00 | 0.00 | 0.00 | 1.79M | 0.00 |
| Net Income | -41.07M | -39.20M | -30.98M | -23.52M | -13.38M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| EPS Diluted | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| Weighted Avg Shares Out | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
| Weighted Avg Shares Out (Dil) | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis,...
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and...
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024.
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to...
Meet the 10 biggest megadonors in the 2024 election cycle so far
Following record-breaking fundraising by candidates in the 2022 midterms, this year's election cycle is shaping up to be another big one for megadonors.
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024.
GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023
Galectin Therapeutics (NASDAQ: GALT ) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents.
Source: https://incomestatements.info
Category: Stock Reports